(Q43568677)

24 November 2017

Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis (English)

1 reference

24 November 2017

Maria Cátira Bortolini

7

object named as

Bortolini M

1 reference

24 November 2017

Ballantyne CM

1

1 reference

24 November 2017

Pazzucconi F

2

1 reference

24 November 2017

Pintó X

3

1 reference

24 November 2017

Reckless JP

4

1 reference

24 November 2017

Stein E

5

1 reference

24 November 2017

McKenney J

6

1 reference

24 November 2017

Chiang YT

8

1 reference

24 November 2017

1 February 2001

1 reference

24 November 2017

Clinical Therapeutics

1 reference

24 November 2017

23

1 reference

24 November 2017

2

1 reference

24 November 2017

177-192

1 reference

Mortality by cause for eight regions of the world: Global Burden of Disease Study

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Systematic review on the risk and benefit of different cholesterol-lowering interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Range of serum cholesterol values in the population developing coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Fluvastatin: a review of its use in lipid disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Pharmacokinetics of fluvastatin and specific drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Comparison of statins in hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980001-1

7 January 2021

10.1016/S0149-2918(01)80001-1

Identifiers

DOI

1 reference

24 November 2017

1 reference